Keeping an Eye on Molecular Imaging: Drug Efficacy & Toxicity in Ophthalmology
Mass spectrometry Imaging (MSI) applications for ophthalmic drug discovery have recently gained growing interest especially for preclinical studies. Drugs for ocular treatment can be easily and quickly assessed for eicacy, safety, and toxicity using MSI. It permits to follow in the same experiment as the bio-distribution of your candidate and associated metabolites, as well as some potential modulation of eicacy or toxicity biomar-kers (peptides, lipids, metabolites). Moreover, the high spatial resolution ability of the technique provides accu-rate localization of compounds in the anterior and posterior segments of the eye which are composed of several histological structures of just a few micrometers. Thus, MSI appears as a tool of choice for evaluating novel target or understanding mechanism of drug action on ocular diseases such as age-related macular degeneration (AMD), diabetic retinopathy, glaucoma, diabetic macular edema (DME), etc.
The combination of classical staining and immunohistology with cutting edge MSI oers new powerful tools to investigate the distribution of various compounds like amphiphilic eye drop excipients with known deleterious eects, and is therefore useful in pharmacological and toxicological preclinical studies. Thanks to high spatial resolution MSI ability, it is possible to follow a drug, drug metabolites, and potential biomarkers for determining eicacy and/or toxicity of treatments